Uganda Heart Institute To Halve Hypertension Treatment

Uganda Heart Institute has signed a memorandum of understanding with Novartis International Pharmaceutical Company to reduce the price of hypertension medication by at least half the normal price.

The reduction in the price is meant to help many Ugandans to be in position to procure medication to treat and control high and low blood pressure at a price less than shs3,800.

Novartis is also in position to provide drugs like Amlodipine, Flutamide and Hydrochlorothiazide, which are used to treat and control low and high blood pressure.

According to Nathan Mulure the head of East and South African clusters at Norvartis, the mentioned drugs can also treat other heart related illnesses like angina, a type of chest pain caused by reduced blood flow to the heart and congestive heart failure.

“This is part of the Novartis Access Programme, a project aimed at providing cheap medication for asthma , hypertension and breast cancer,” he revealed.

Mulure also added that the agreement is aimed at providing cheap drugs to all sick people that need them.

“The drugs will also be supplied to private healthcare providers like pharmacies at the cost of USD (shs 7,600), through Surgipharm Uganda as the supplier to privately owned pharmacies.”

Mulure cautioned pharmacies against increasing the prices of the drugs adding that they will not work with pharmacies that sell the drugs at a cost higher than the set price.


Dr Peter Lwabi, the Deputy Executive Director of the Uganda Heart Institute is optimistic that the agreement will ease access to medicines for people suffering from hypertension.

Research by the Ministry of health shows that one in every four Ugandans suffers from high or low blood pressure and that less than 70 percent of Ugandans are aware of their blood pressure status.

Back to top button
Translate »

Adblock Detected

Please consider supporting us by disabling your ad blocker